Supekar R, Sarkar J, Chakrabarti P, Biswas S
Arch Virol. 2025; 170(4):71.
PMID: 40063291
DOI: 10.1007/s00705-025-06256-y.
Fu J, Biao R, Liu Y, Chen J, Zhao H
Ann Med. 2025; 57(1):2470957.
PMID: 39992020
PMC: 11852214.
DOI: 10.1080/07853890.2025.2470957.
Fu M, Elsharkawy A, Healy B, Jackson C, Bradshaw D, Watkins E
EClinicalMedicine. 2025; 81:103095.
PMID: 39975699
PMC: 11836515.
DOI: 10.1016/j.eclinm.2025.103095.
Huang C, Zhang H, Wang J, Li J, Liu Q, Zong Q
Open Life Sci. 2025; 20(1):20220951.
PMID: 39926475
PMC: 11806202.
DOI: 10.1515/biol-2022-0951.
Kopacz A, Kubicka-Russel D, Liszewski G, Sulkowska E, Chrzanowska A, Zwolinska P
Viruses. 2025; 17(1).
PMID: 39861849
PMC: 11768870.
DOI: 10.3390/v17010060.
New Insights on Hepatitis B Virus Viral Transcription in Single Hepatocytes.
Peng B, Pan L, Li W
Viruses. 2025; 16(12.
PMID: 39772138
PMC: 11680359.
DOI: 10.3390/v16121828.
The hidden epidemic of occult hepatitis B and C among injection drug users (IDUs): A call for action.
Elkashef K, Abdel Fattah N, Mesbah N, El-Shaarawy F, Amer M, Fakhr A
Int J Health Sci (Qassim). 2025; 19(1):22-30.
PMID: 39760055
PMC: 11699232.
Multi-omic molecular characterization and diagnostic biomarkers for occult hepatitis B infection and HBsAg-positive hepatitis B infection.
Jiang X, Tian J, Song L, Meng J, Yang Z, Qiao W
Front Endocrinol (Lausanne). 2024; 15:1409079.
PMID: 39600945
PMC: 11588476.
DOI: 10.3389/fendo.2024.1409079.
Unlocking the Potential of Phyto Nanotherapeutics in Hepatocellular Carcinoma Treatment: A Review.
Bhange M, R Telange D
J Hepatocell Carcinoma. 2024; 11:2241-2256.
PMID: 39574434
PMC: 11579138.
DOI: 10.2147/JHC.S483619.
Hepatitis B surface antigen-negative but hepatitis B envelope antigen-positive false occult hepatitis B virus infection: A case report.
Yang S, Fu F, Xuan Q, Zhang Z, Li Z, Li G
World J Hepatol. 2024; 16(10):1199-1207.
PMID: 39474578
PMC: 11514620.
DOI: 10.4254/wjh.v16.i10.1199.
Advances in the Elimination of Viral Hepatitis in Mexico: A Local Perspective on the Global Initiative.
Santos-Lopez G, Panduro A, Sosa-Jurado F, Fierro N, Lira R, Marquez-Dominguez L
Pathogens. 2024; 13(10).
PMID: 39452730
PMC: 11510378.
DOI: 10.3390/pathogens13100859.
Incidence of Occult Hepatitis B Infection (OBI) and hepatitis B genotype characterization among blood donors in Cameroon.
Mbencho M, Hafza N, Chi Cao L, Mingo V, Achidi E, Ghogomu S
PLoS One. 2024; 19(10):e0312126.
PMID: 39413100
PMC: 11482724.
DOI: 10.1371/journal.pone.0312126.
p-STAT3-elevated E3 ubiquitin ligase DTX4 confers the stability of HBV cccDNA by ubiquitinating APOBEC3B in liver.
Zhao L, Yuan H, Wang Y, Hou C, Lv P, Zhang H
Theranostics. 2024; 14(15):6036-6052.
PMID: 39346550
PMC: 11426250.
DOI: 10.7150/thno.99407.
An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.
Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A
Heliyon. 2024; 10(17):e37097.
PMID: 39281486
PMC: 11402251.
DOI: 10.1016/j.heliyon.2024.e37097.
Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.
La Mura V, Cardinale V, De Cristofaro R, De Santis A, Di Minno G, Fabris L
Blood Adv. 2024; 8(22):5725-5734.
PMID: 39226466
PMC: 11599981.
DOI: 10.1182/bloodadvances.2024013750.
Occult Hepatitis B Virus Infection in Hepatic Diseases and Its Significance for the WHO's Elimination Plan of Viral Hepatitis.
Bucio-Ortiz L, Enriquez-Navarro K, Maldonado-Rodriguez A, Torres-Flores J, Cevallos A, Salcedo M
Pathogens. 2024; 13(8).
PMID: 39204261
PMC: 11357063.
DOI: 10.3390/pathogens13080662.
First Detection of Hepatitis B Virus Subgenotype A5, and Characterization of Occult Infection and Hepatocellular Carcinoma-Related Mutations in Latin American and African Immigrants in Brazil.
SantAnna T, Martins T, Carneiro M, Teles S, Caetano K, de Araujo N
Int J Mol Sci. 2024; 25(16).
PMID: 39201291
PMC: 11354843.
DOI: 10.3390/ijms25168602.
Analysis of hepatitis B Virus Test results among blood donors in Chongqing, China.
Wei L, Chen M, Wang F, Li M, Liu D, Xie C
BMC Infect Dis. 2024; 24(1):857.
PMID: 39179973
PMC: 11342658.
DOI: 10.1186/s12879-024-09753-8.
Harnessing the evolving CRISPR/Cas9 for precision oncology.
Li T, Li S, Kang Y, Zhou J, Yi M
J Transl Med. 2024; 22(1):749.
PMID: 39118151
PMC: 11312220.
DOI: 10.1186/s12967-024-05570-4.
Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis.
Lazarevic I, Miljanovic D, Banko A, Cupic M, Cirkovic A
Viruses. 2024; 16(7).
PMID: 39066283
PMC: 11281513.
DOI: 10.3390/v16071121.